All Episodes

September 5, 2024 22 mins

Mark shares his experience with recurrent prostate cancer and his journey through radiation treatment. He discusses the use of ADT medication to reduce testosterone levels before radiation, the side effects of ADT, the process of radiation treatment, and the emotional journey of completing treatment. Mark also talks about the importance of early detection and the advancements in prostate cancer treatment that may eliminate the need for surgery in the future.  He is now finished with treatment, and will stop taking the ADT.  He wants his Mojo back.

Takeaways

ADT medication is used to reduce testosterone levels before radiation treatment for prostate cancer.

Side effects of ADT medication can include hot flashes, moodiness, and weight gain.

Radiation treatment for prostate cancer can cause fatigue and minor bladder irritation.

Early detection of prostate cancer increases the chances of successful treatment.

Advancements in prostate cancer treatment may eliminate the need for surgery in the future.

Chapters
00:00 Introduction and Background
04:41 The Radiation Machine and Completing Treatment
08:39 Starting Radiation Treatment
13:30 Side Effects and Weight Gain
17:12 The Journey Continues and the Future of Prostate Cancer Treatment

Mark as Played

Advertise With Us

Popular Podcasts

United States of Kennedy
Dateline NBC

Dateline NBC

Current and classic episodes, featuring compelling true-crime mysteries, powerful documentaries and in-depth investigations. Follow now to get the latest episodes of Dateline NBC completely free, or subscribe to Dateline Premium for ad-free listening and exclusive bonus content: DatelinePremium.com

Stuff You Should Know

Stuff You Should Know

If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.

Music, radio and podcasts, all free. Listen online or download the iHeart App.

Connect

© 2025 iHeartMedia, Inc.